Comparison of the Treatment of Retinopathy of Prematurity in Bevacizumab vs Ranibizumab: A Systematic review and Meta-analysis

International Journal of Industrial Chemistry

مقاله 1، دوره 13، شماره 2، شهریور 2022

نوع مقاله: research article

شناسه دیجیتال (DOI): 10.47176/IJIC.13.2.1

نویسندگان

Shina Li¹؛ Fang Yue²؛ Yeting Zhang³؛ Meili Yu^{* 1}

¹Department of Neonatology, Yuhuangding Hospital, Yantai, Shandong 264000, China

²Department of Pediatrics, Yuhuangding Hospital, Yantai, Shandong 264000, China

³Department of Pediatric Ward, Zhifu District Maternity and Child Care Hospital, Yantai, Shandong 264000, China

چکیده

Background: Intravitreal injections of ranibizumab (IVR) and bevacizumab (IVB) have both been used as treatments for retinopathy of prematurity (ROP). We performed a meta-analysis of the published literature comparing outcomes after either IVR to IVB for the treatment of ROP in infants.
Methods: We performed an electronic search in PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials), and Google Scholar databases for published articles from 1950 to 2021 comparing outcomes (including recurrence rates, aggressive posterior retinopathy of prematurity [APROP], vascularization rate, vascularization time, axial length, and spherical equivalence) of treatment with bevacizumab and ranibizumab in patients with ROP.
Results: We included 11 studies comparing outcomes after bevacizumab and ranibizumab for the treatment of ROP. The recurrence rate was lower after IVB than after IVR (Risk Ratio [RR] = 0.36; 95% CI, 0.26 to 0.51; I2 = 44%). We found similar APROP (RR = 0.63; 95% CI, 0.38 to 1.04; I2 = 38%) and vascularization (RR = 1.11; 95% CI, 0.75 to 1.63; I2 = 63%) rates, vascularization times (SMD = 0.29; 95% CI, -0.31 to 0.89; I2 = 59%), axial lengths (SMD =0.48; 95% CI, -0.07 to 1.02; I2 = 79%), and spherical equivalences (SMD =-0.33; 95% CI, -0.72 to 0.02; I2 = 69%). No significant publication bias was observed.
Conclusions: Our findings suggest a lower recurrence rate of ROP in patients treated with IVB than in those treated with IVR. Further studies are needed to evaluate the optimal treatment and follow-up strategies for ROP treatment.

کلیدواژه‌ها

Bevacizumab؛ Ranibizumab؛ Retinopathy of Prematurity؛ anti-VEGF؛ vascular endothelial growth factor